$MSOS $TLRY $CGC $ACB: Cannabis Rescheduling Hearing Update After DEA Recess Order Shifts the July 9 Schedule

1. Where the DEA hearing stands now

The official DEA hearing is underway at DEA Headquarters in Arlington, Virginia. The proceeding is scheduled from June 29 through July 15, 2026, from 9:00 a.m. to 5:00 p.m. ET. The DEA has stated that the hearing is open to the public and credentialed media in limited capacity, with no video or audio recording permitted inside the courtroom or adjoining lobby area.

That matters because the information flow is imperfect. This is not a televised Congressional hearing. It is a formal administrative proceeding. Investors are therefore working from official orders, Federal Register notices, in-room reporting, legal commentary, party statements and, eventually, the official record itself. That creates a classic cannabis-market problem: headlines can move first, but the legally important details may arrive later.

The purpose of the hearing is to receive factual evidence and expert opinion regarding whether marijuana should be transferred from Schedule I to Schedule III. That language is not cosmetic. The final agency action, and any later court review, will not be based on social-media sentiment or sector enthusiasm. It will be based on whether the administrative record supports the statutory findings needed for Schedule III.

2. The official participant map

The DEA selected seven outside interested persons for the hearing, in addition to the government. The list is important because it explains the shape of the record. The government is defending the Schedule III proposal; the outside participants are trying to expose weaknesses in that proposal from different legal, scientific, enforcement and public-safety angles.

3. The official calendar through July 15

The official DEA schedule assigns dates for each party to begin its case-in-chief, but the calendar has now been amended. The simplified headline calendar is useful, but the detailed schedule is more nuanced because several witness examinations can continue across days, and the ALJ can recess the hearing when a designated party finishes before the next party is scheduled to begin. DUID Victim Voices began on July 7 and continued into July 8. Kenneth Finn began and concluded on July 8. The hearing is in recess on July 9. TBI begins on July 10. Phillip Drum begins on July 13, and the States begin on July 14.

The important point is not simply which side “wins” a day of testimony. The important point is which arguments enter the record cleanly enough to matter later. A weak cross-examination may create noise. A strong cross-examination may create legal ammunition. That is why the July 5 piece focused on the anti-Schedule III case rather than just the Schedule III headline.

4. What the government is trying to prove

The government does not need to prove that marijuana is harmless. It does not need to prove that adult-use legalization is good policy. It does not need to solve banking. It does not need to make cannabis look like a conventional FDA-approved single-molecule drug.

The government’s burden is narrower: support the transfer of marijuana from Schedule I to Schedule III by showing that marijuana has currently accepted medical use in treatment in the United States, has a potential for abuse less than substances in Schedules I and II, and has a dependence profile compatible with Schedule III treatment.

That distinction matters because opponents are attacking exactly those pillars. They are arguing that the medical-use test was changed, that botanical cannabis lacks reproducible chemistry, that state programs create diversion, that impaired driving and public-health risks are underweighted, and that the data used in the government’s evaluation may not fully reflect the current market.

5. Why CAMU is the center of the fight

CAMU means “currently accepted medical use.” It sounds technical, but for this hearing it is central. Under the Controlled Substances Act, a Schedule I substance is defined by high abuse potential, no currently accepted medical use in treatment in the United States, and lack of accepted safety under medical supervision. If marijuana has CAMU, the Schedule I framework becomes much harder to defend.

This is why the debate over the CAMU test matters. The government’s modern approach relies on a framework that looks at accepted medical use through broader clinical experience and scientific support. Opponents prefer a stricter standard that emphasizes reproducible chemistry, adequate safety studies, adequate and well-controlled efficacy studies, expert acceptance and widely available scientific evidence.

This is also why the “botanical cannabis is variable” argument keeps appearing. If the standard requires a drug-like product with reproducible chemistry, raw cannabis is vulnerable. If the standard can recognize accepted medical use based on broader clinical experience, state medical programs and scientific support, Schedule III becomes more plausible.

6. What the first stretch showed

The first stretch of the hearing produced a mixed but important record. The constructive part for the cannabis trade is that the government did not appear passive. Public reporting from the room described the government as the proponent of the proposed rule and made clear that the proceeding is not about recreational legalization. The government’s witness structure also pointed toward the two pillars it wants to establish: scientific/medical analysis and clinical experience.

The first government witness, Dominic Chiapperino, Ph.D. of FDA/CDER, was positioned around the FDA/HHS scientific and medical evaluation. Cannabis Business Times described the government as arguing in support of currently accepted medical use, while anti-rescheduling participants attempted to expose flaws in the Schedule III recommendation.

The second government witness identified before the hearing was Corey Burchman, M.D., a pain-management physician with experience involving medical marijuana in pain patients. That matters because it gives the government a practical clinical-use narrative, not only a document-based scientific analysis.

The negative part for the trade is that cross-examination pressure has highlighted exactly the risk areas we were watching: data recency, product variability, diversion, hemp-derived cannabinoid crossover, impaired driving, the absence of conventional FDA-style prescribing and dispensing controls for state-licensed cannabis, and the difference between “recommendation” and “prescription.”

7. The headline problem: live readouts are not the official record

The cannabis sector is extremely sensitive to hearing-room snippets, advocacy summaries and short readouts. That is dangerous in this proceeding. A party statement may be directionally useful, but it is not the same as the official transcript, the exhibit record or the ALJ’s later recommendation.

The right way to use live readouts is to identify pressure points, not to treat them as final truth. Claims about internal scientific disagreement, product standardization, state-program diversion, impaired driving or CAMU weakness become materially important only if they are confirmed in the official record and are strong enough to affect the agency’s final reasoning or later judicial review.

8. The legal path after July 15

July 15 is not the final rescheduling decision. It is the scheduled end of the hearing. The July 9 recess does not change that basic point. After the hearing closes, the administrative law judge will work from the record and issue a recommended decision. The DEA then decides whether to issue a final rule, modify the proposal, slow the process, or take another legally permissible route. Whatever the agency does, litigation is likely.

Reuters and legal commentators have already framed the April 2026 cannabis action as a limited shift rather than federal legalization. Reuters also reported on July 8 that three petitions challenging the April order have been consolidated before the D.C. Circuit, reinforcing the point that the cannabis policy trade is now running on both an administrative track and an appellate litigation track. The broader marijuana proposal now depends on the hearing record being built in this proceeding. That distinction is central for investors: the first action created a narrower medical-cannabis pathway; the current hearing is about whether a broader Schedule III treatment can be legally supported.

For investors, the takeaway is simple: the catalyst does not end on July 15. The hearing window can move stocks because it provides daily headlines. The larger value inflection comes later, when the market sees whether the DEA moves toward a broad final rule and whether courts allow that rule to stand.

9. What Schedule III would change — and what it would not

Schedule III would be meaningful, but not magical. The cleanest potential economic effect is tax-related: Internal Revenue Code Section 280E applies to trafficking in Schedule I and II substances, so Schedule III treatment can reduce the tax burden for covered cannabis operators. This is why the cannabis trade cares so much about rescheduling even without full legalization.

But Schedule III would not automatically create a national adult-use cannabis market. It would not automatically solve banking. It would not authorize interstate adult-use commerce by itself. It would not erase state licensing regimes. It would not remove all federal criminal and regulatory risk. It would not make every cannabis business instantly investable for institutions.

The April 2026 partial order already created a medical-cannabis lane, but adult-use operators remain outside the cleanest relief unless the broader rescheduling process changes the treatment of marijuana more generally. That is why this hearing matters for $MSOS and for the high-beta cannabis basket.

10. Ticker read-through: $MSOS, $TLRY, $CGC, $ACB and $CRON

For Merlintrader, the listed cannabis watchlist should stay focused on exchange-traded names and liquid proxies. Many U.S. plant-touching MSOs remain OTC or structurally awkward for the site’s usual filter, so $MSOS remains the cleanest listed policy proxy even though the fund itself holds a basket and is not a single operating company.

$MSOS — the cleanest U.S. policy proxy

$MSOS is the most direct listed way for many traders to express a view on U.S. cannabis policy. It is not a perfect proxy, because ETF structure, holdings composition, liquidity and derivatives mechanics can all distort short-term moves. But if the market starts pricing a broader Schedule III path, $MSOS is likely to be one of the first instruments to react.

The key risk is that $MSOS can move violently on headlines that later prove incomplete. A “hearing positive” readout can trigger a rally; a litigation or procedural headline can reverse it. This is why the record-building nature of the hearing is more important than a simple calendar date.

$TLRY — liquid global cannabis sentiment, but not a pure U.S. rescheduling play

Tilray remains one of the most liquid cannabis tickers for Nasdaq traders. Its exposure includes Canadian cannabis, international medical cannabis, distribution and beverage assets. That makes $TLRY useful as a sentiment trade, but imperfect as a direct U.S. policy beneficiary. It may move with cannabis enthusiasm even when the fundamental benefit is less direct than for U.S. operators.

The market tends to treat $TLRY as a high-beta cannabis narrative vehicle. That can be useful during a policy momentum phase, but readers should separate liquidity and meme sensitivity from direct tax or operating benefit.

$CGC — high-beta turnaround exposure

Canopy Growth is still a high-volatility cannabis turnaround story. The ticker can react sharply to sector headlines because the brand remains familiar and the historical cannabis-cycle memory is strong. But the operational and balance-sheet history is messy, and the stock should not be treated as a clean legal-policy derivative.

For this hearing, $CGC is best understood as a sentiment amplifier. If Schedule III momentum gets stronger, $CGC can participate. If the hearing turns into a procedural/legal risk story, the same volatility can work in reverse.

$ACB — cleaner global medical-cannabis lens

Aurora Cannabis has increasingly become a cleaner medical and international cannabis profile compared with the older Canadian LP hype cycle. In a world where the U.S. discussion is moving from pure prohibition toward regulated medical recognition, $ACB can fit the theme better than some meme-heavy peers.

That does not make $ACB a direct U.S. rescheduling winner. It means the narrative around regulated medical cannabis, international standards and non-U.S. medical markets may become more investable if the U.S. federal conversation validates medical use more broadly.

$CRON — balance-sheet sensitivity and lower-hype optionality

Cronos is often less explosive than the most speculative cannabis names, but it can matter when the market starts filtering cannabis exposure through cash, balance-sheet strength and survivability. If the policy trade shifts from pure meme to “which cannabis companies can actually survive and benefit,” $CRON deserves a place on the watchlist.

$SNDL — diversified Canadian exposure, but less direct

$SNDL can move with the sector, but it is less directly tied to the U.S. Schedule III catalyst than $MSOS and less clean as a medical-cannabis read-through than $ACB. It remains a liquidity and sentiment watch item rather than a core policy proxy.

11. Bull, neutral and bear scenarios

12. The trading takeaway

The cannabis trade is alive, but it is not clean. The hearing is real. The Schedule III pathway is real. The government support is real. But the opposition record is also real, and the end of the hearing is not the same as a final agency rule.

The cleanest interpretation is this: the July 15 window is a record-building catalyst, not a final legalization catalyst. Cannabis tickers can move ahead of the conclusion because markets discount probability before formal legal completion. But every rally must be viewed against the possibility of litigation, implementation delays and headline reversals.

For $MSOS, the question is whether traders begin to price a broader U.S. policy repricing. For $TLRY and $CGC, the question is whether liquid cannabis sentiment rotates back into high-beta Nasdaq names. For $ACB, the question is whether medical cannabis credibility becomes more valuable. For $CRON, the question is whether the market starts rewarding cleaner balance sheets after the first sentiment wave.

13. Watchlist through July 15

14. What would make the story materially better?

The story improves if the official transcript confirms that the government’s witnesses defended the Schedule III findings effectively, if the ALJ keeps the hearing tightly focused on the statutory question, if opponents fail to create a material defect in the record, and if DEA signals a clean path toward a final rule after the July 15 close.

A constructive record would not eliminate lawsuits, but it would reduce the odds that a court views the final rule as arbitrary, procedurally defective or unsupported by substantial evidence. That is the real bull case. Not hype. Durability.

15. What would make the story materially worse?

The story worsens if the official record shows meaningful internal conflict between HHS/FDA and DEA scientific analysis, if the older five-part CAMU test becomes a strong litigation weapon, if data recency becomes a credible flaw, or if state-program diversion and impaired-driving evidence create a more powerful public-safety record than the government anticipated.

The worst version for the trade is not simply “opponents say cannabis is bad.” The worst version is: opponents show that the agency changed standards, omitted important risks, relied on stale data, failed to handle product variability and did not build a record strong enough for judicial review.

16. Bottom line

The DEA hearing is now the cannabis market’s main short-term policy event. The setup is strong enough to keep $MSOS, $TLRY, $CGC, $ACB and $CRON on watch. But the catalyst is not clean enough to treat as an all-clear.

For now, the cannabis sector remains a policy-driven, headline-sensitive, high-volatility watchlist. The latest update is procedural but important: Kenneth Finn has concluded, July 9 is an official recess, and the next substantive session is TBI on July 10. After that, Phillip Drum and the state coalition remain the key remaining witness blocks before the July 15 window closes. Each can add risk or clarity to the record. The hearing is not over. The trade is not settled. The record is still being written.

Merlintrader Trading Pub · Educational market coverage · U.S. equities and policy catalysts